Dr. Zheng is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
University of Kansas Medical Center
3901 Rainbow Blvd
Kansas City, KS 66160Phone+1 913-588-7071Fax+1 913-588-7073- Is this information wrong?
Summary
- I am board certified pathologist, specialized in laboratory medicine, transfusion medicine, and coagulation. My laboratory focuses on understanding the molecular mechanism of thrombotic thrombocytopenic purpura (TTP) and atypical hemolytic uremic syndrome and developing novel diagnostic and therapeutic tools for these rare but potentially fatal disorders.
Education & Training
- Washington University/B-JH/SLCH ConsortiumFellowship, Blood Banking/Transfusion Medicine, 2002 - 2003
- Washington University/B-JH/SLCH ConsortiumResidency, Pathology-Anatomic and Clinical, 1999 - 2002
- University of ViennaPh.D., Mol. Cell. Biology, 1991 - 1994
- Tongji Medical College, Huazhong University of Science and TechnologyMSc, Obs/Gyn, 1987
- Medical College of Nanchang UniversityClass of 1984, M.D.
Certifications & Licensure
- Alabama Sate Medical License, AL 2014 - Present
- PA State Medical License 2003 - 2024
- KS State Medical License 2020 - 2024
- NJ State Medical License 2008 - 2021
- American Board of Pathology Clinical Pathology
- American Board of Pathology Blood Banking/Transfusion Medicine
Awards, Honors, & Recognition
- Distinguished pathologist award Chinese American Pathologists Association, 2024
- Gift-of-Life Award RayWinn Foundation, NJ, 2014
- Karl-Link New Investigator Award for Hemostasis ATVB, American Heart Association, 2012
- Join now to see all
Publications & Presentations
PubMed
- Mechanism underlying severe deficiency of plasma ADAMTS-13 activity in immune thrombotic thrombocytopenic purpura.Zheng, X., X Long Zheng> ;Journal of Thrombosis and Haemostasis. 2024 May 1
- A descriptive analysis of fatal outcomes in immune thrombotic thrombocytopenic purpura in the USTMA TTP Registry.Abou-Ismail, M., Zheng, X., Woods, R., Mouhamed Yazan Abou-Ismail, Chong Zhang, Angela P Presson, Shruti Chaturvedi, Ana G Antun, Andrew M Farland, Ryan Woods, Ara Met...> ;Blood Advances. 2024 Feb 13
- Altered cleavage of human factor VIII at the B-domain and acidic region 3 interface enhances expression after gene therapy in hemophilia A mice.Giang N Nguyen, Jonathan R Lindgren, Maria C Seleme, Samita Kafle, Catherine B Zander, X Long Zheng, Denise E Sabatino, Zheng, X.> ;Journal of Thrombosis and Haemostasis. 2023 Aug 1
- Join now to see all
Journal Articles
- Understanding thrombotic microangiopathies in childrenJoly BS, Zheng XL and Veyradier A, Inten Care Med, 1/24/2018
- Low Plasma ADAMTS13 Activity is Associated with Coagulopathy, Endothelial Cell Damage and Mortality after Severe Pediatric TraumaRussell RT, McDaniel JK, Cao WJ, Shroyer M, Wagener BM, Zheng XL (corr. au.), JF Pittet, Thromb Haemost, 1/1/2018
- Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia ANguyen GN, George LA, Siner JI, Davidson RJ, Zander CB, Zheng XL, Arruda VR, Camire RM, Sabatino DE, J Thromb Haemost, 1/1/2017
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Longitudinal Assessment of Plasma ADAMTS13 Biomarkers Helps Predict Recurrence of Immune Thrombotic Thrombocytopenic PurpuraX. Long Zheng, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Plasma Levels of Histone-DNA Complex and Cell-Free DNA Predict Mortality in Patients with Immune Thrombotic Thrombocytopenic PurpuraX. Long Zheng, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- African American Race Is Associated with Decreased Relapse-Free Survival in Immune Thrombotic Thrombocytopenic PurpuraX. Long Zheng, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- TTP: from bench to bedsideSan Francisco, CA - 1/1/2018
- aHUS: Evidence Based Guidelines in Therapeutic ApheresisDallas, TX - 1/1/2018
- HUS: Dual Presentation Diagnosis and TreatmentWestchester Medical Center, Valhalla, NY - 1/1/2018
- Join now to see all
Grant Support
- Novel Therapeutics for Thrombotic Thrombocytopenic PurpuraNHLBI2019–2024
- Zebrafish model of Thrombotic Thrombocytopenic PurpuraAmerican Heart Association (Mentor)2019–2020
- Complement activation in pathogenesis of TTPAnswering T.T.P. Foundation2015–2020
- Pathogenesis of Thrombotic MicroangiopathyNHLBI2015–2020
- Structure and function of ADAMTS13NHLBI2005–2010
- Cofactor-dependent regulation of VWF proteolysisNHLBI2005–2010
Committees
- Member, ISTH 2024 symposium planning 2023 - Present
- Co-chair, ISTH SSC 2022 - Present
- Member, NIH HTBT study section 2018 - Present
Research History
- Professor at University of Alabama at Birmingham, Birmingham, AL2015 - 2020
- Associate Professor at University of Pennsylvania, Philadelphia, PA2011 - 2015
- Assistant Professor at University of Pennsylvania, Philadelphia, PA2003 - 2011
- Postdoctoral fellow, Washington University in St. Louis, MO1995 - 1999
Professional Memberships
- Member
- Member
- Member
- Academy of Laboratory Physicians and ScieintistsMember
- International Society of Thrombosis and HaemostasisMember
- American Association of Blood Bank and Cellular TherapyMember
- Association of Pathology ChairsMember
Other Languages
- Chinese (Mandarin), German
Hospital Affiliations
- The University of Kansas HospitalKansas City, Kansas
Industry Relationships
- Consultant, Sanofi2020 - Present
- Consultant, Takeda2019 - Present
- Co-founder, Clotsolution2018 - Present
- Speaker, Sanofi-Genzyme2019 - 2020
- Speaker, Alexion2012 - 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: